Femasys Inc. (FEMY) announced on Tuesday that it has received regulatory approval from the UK's Medicines & Healthcare products Regulatory Agency or MHRA for its FemaSeed Intratubal Insemination product, along with FemVue and FemCerv diagnostic devices.
The approval follows successful clearances in the U.S., Europe, Canada, and Israel.
FemaSeed is a groundbreaking infertility treatment that enhances fertilization by delivering sperm directly into the fallopian tube.
FemVue provides a reliable, real-time ultrasound evaluation of the fallopian tubes, while FemCerv offers a non-invasive, pain-free method for cervical cancer detection.
These approvals further extend Femasys' global reach, enabling the company to offer innovative, accessible healthcare solutions for women's health in the UK.
Femasys continues to lead the way in minimally invasive women's health solutions with its portfolio of FDA-cleared and internationally approved products.
Currently, FEMY is trading at $1.28 up by 10.34%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.